All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2017-01-17T11:51:26.000Z

Rituximab biosimilar, TruximaTM, given ‘positive opinion’ by the EMA CHMP for use in CLL and NHL

Jan 17, 2017
Share:

Bookmark this article

On the 15th December 2016, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) gave a positive opinion for granting marketing authorization for TruximaTM, a rituximab biosimilar monoclonal antibody targeting CD20 in B-cells. The marketing approval application for TruximaTM was submitted by Celltrion Healthcare Hungary Kft. The CHMP concluded that TruximaTM shows “comparable quality, safety, and efficacy to Mabthera® (rituximab)” from Roche.

The CHMP gave positive opinions for using TruximaTM in combination with chemotherapy in first-line FL patients with stage III–IV disease, and for use as maintenance therapy following an induction response. TruximaTM is also indicated for use in stage III–IV FL patients resistant or who relapse following first-line chemotherapy. The CHMP positive opinion also includes an indication for use in CD20-positive DLBCL in combination with CHOP-based chemotherapy, and an indication for use in untreated and R/R CLL patients in combination with chemotherapy.

TruximaTM is proposed to be available in 500mg solutions for infusion and the data for the use of this drug is based on the previous EMA approval of Mabthera® (rituximab). The full indication for TruximaTM is listed below:

“Non-Hodgkin’s lymphoma (NHL)

Truxima is indicated for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy. 

Truxima maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy.

Truxima monotherapy is indicated for treatment of patients with stage III-IV follicular lymphoma who are chemo-resistant or are in their second or subsequent relapse after chemotherapy.

Truxima is indicated for the treatment of patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.

Chronic lymphocytic leukemia (CLL)

Truxima in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including Truxima or patients refractory to previous Truxima plus chemotherapy.”

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

Given there are no currently approved treatment options for patients with Waldenstrom’s macroglobulinemia in the third-line setting, what major response rate threshold would make you consider adopting a new radiotherapy option in this setting?
1 vote - 6 hours left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox